Ascentage Pharma Group International vs Legend Biotech
AAPG and LEGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AAPG and LEGN compare
Legend Biotech grew revenue faster over the last twelve months (59.5% versus −41.5% for Ascentage Pharma Group International).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AAPG | LEGN |
|---|---|---|
| Size and price | ||
| Share price | $13.14 | $16.11 |
| Change, 1 year | −61.7% | −46.8% |
| Change, 5 years | – | −70.2% |
| Beta (5Y) | 1.43 | 0.80 |
| Employees | 767 | 2,900 |
| StockData Score | ||
| Total score | 3 | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −41.5% | 59.5% (better) |
| Revenue growth, 5Y average | – | 68.8% |
| Profitability | ||
| Gross margin | 91.5% (better) | 57.2% |
| Operating margin | – | −4.3% |
| Net margin | −216% | – |
| FCF margin | −209% | −9.6% (better) |
| Return on equity | −156% | – |
| Financial health | ||
| Debt / equity | 1.50 | – |
| Interest coverage | – | −2.5× |
| Current ratio | 1.79 | 3.04 (better) |
| Ownership | ||
| Held by institutions | 0.00% | 28.4% |
| Held by insiders | 13.0% | 0.50% |
| Insider net buying, 12 months | – | −$384K |
| Superinvestors holding | – | 1 |
Go deeper
- AAPG stock overview
- AAPG income statement
- AAPG valuation and score
- LEGN stock overview
- LEGN income statement
- LEGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.